Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC. [1] He was vice president of research and operations at Stratagene (now Agilent Technologies), president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005. [2] While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly, [3] and was the first to combine these discovery and evolution technologies.
On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's conditionally-active biologics (CAB) antibody platform and Pfizer's antibody-drug conjugate (ADC) payloads. [4] BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales. [5]
Short is also founder of the E. O. Wilson Biodiversity Foundation, [6] chairman of the board of Ciris Energy, [7] and member of the board of directors of Senomyx. [8] Short received his Ph.D. in biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in chemistry from Taylor University in Upland, Indiana.
{{
cite web}}
: CS1 maint: archived copy as title (
link)
Jay M. Short is founder and CEO of the antibody drug company BioAtla, LLC. [1] He was vice president of research and operations at Stratagene (now Agilent Technologies), president of the Stratagene antibody subsidiary Stratacyte, then founder and CEO of Diversa until 2005. [2] While at Diversa, Short invented methods of protein and pathway discovery via metagenomics, in addition to evolution technologies gene site saturation mutagenesis (GSSM) and GeneReassembly, [3] and was the first to combine these discovery and evolution technologies.
On December 7, 2015, San Diego-based BioAtla signed a license and option deal with Pfizer, involving BioAtla's conditionally-active biologics (CAB) antibody platform and Pfizer's antibody-drug conjugate (ADC) payloads. [4] BioAtla is eligible to receive more than $1.0 billion in up-front, regulatory and sales milestone commitments as well as tiered marginal royalties reaching double digits on potential future product sales. [5]
Short is also founder of the E. O. Wilson Biodiversity Foundation, [6] chairman of the board of Ciris Energy, [7] and member of the board of directors of Senomyx. [8] Short received his Ph.D. in biochemistry from Case Western Reserve University in Cleveland, Ohio and his B.A. with honors in chemistry from Taylor University in Upland, Indiana.
{{
cite web}}
: CS1 maint: archived copy as title (
link)